Research programme: IPL5 series - Aventis/Inflazyme

Drug Profile

Research programme: IPL5 series - Aventis/Inflazyme

Alternative Names: IPL5 series research programme - Aventis/Inflazyme; LSAIDs research programme - Aventis/Inflazyme; Research programme: LSAIDs - Aventis/Inflazyme

Latest Information Update: 15 Feb 2005

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Inflazyme Pharmaceuticals
  • Class
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Inflammation

Most Recent Events

  • 15 Feb 2005 Inflazyme Pharmaceuticals is winding down its LSAIDs™ collaboration with sanofi-aventis
  • 30 Jul 2004 No development reported - Preclinical for Inflammation in Canada (unspecified route)
  • 24 Feb 2000 IPL 576 compounds are being investigated for potential in atopic dermatitis and allergic conjunctivitis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top